Ultragenyx is trading 4.01% up now at $26.95 after investors continued reacting to its record second-quarter results.
- Q2 revenue reached $214 million, beating $181 million consensus; loss of $0.90 per share was narrower than the expected $1.27 loss.
- Strong Crysvita, Dojolvi, and Evkeeza demand supported growth; management reaffirmed 2026 revenue guidance.
- The broader market was roughly flat on August 10; company-specific earnings momentum appears the primary driver. Trading remains active during the open session, but reliable volume data was unavailable.